Literature DB >> 8631031

erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.

S P Ethier1, K E Kokeny, J W Ridings, C A Dilts.   

Abstract

A new human breast cancer cell line (SUM-52PE), originating from a malignant pleural effusion specimen, that can be cultured under serum-free conditions has been isolated. Experiments were conducted to examine the relationship between expression of the erbB family of growth factor receptors and growth regulation in these cells. SUM-52PE cells are epidermal growth factor receptor negative but express single copy levels of erbB-2 protein. Southern blot analysis indicates that the erbB-2 gene is not amplified in these cells. The cells also express mRNA for both erbB-3 and erbB-4. Phosphotyrosine Western blot analysis of membrane protein obtained from SUM-52PE cells indicates the presence of a constitutively tyrosine phosphorylated M(r) 185,000 protein. Immunoprecipitation, using antibodies to erbB-2 or erbB-3, coupled to phosphotyrosine Western blot analysis indicates that both erbB-2 and erbB-3 are constitutively tyrosine phosphorylated in proliferating SUM-52PE cells. Conditioned medium obtained from SUM-52PE cells does not induce tyrosine phosphorylation of p185erbB-2 in a sensitive indicator cell line, suggesting that an erbB-2 activating factor is not secreted by these cells. However, neu differentiation factor/heregulin (NDF/HRG) mRNA is expressed by the cells, and Western blot analysis of SUM-52PE membrane protein revealed the presence of a M(r) 90,000 immunoreactive NDF/HRG protein. Thus, SUM-52PE cells synthesize a membrane bound form of NDF/HRG that may activate erbB-2 and erbB-3 via a juxtacrine mechanism. The addition of exogenous beta-2-NDF/HRG to the culture medium of SUM-52PE cells yields enhanced tyrosine phosphorylation of p185erbB-2/erbB-3 but has only a small stimulatory effect on the proliferation of these cells. By contrast, an erbB-2 monoclonal antibody that binds to the extracellular domain of erbB-2 is potently mitogenic for these cells. SUM-52PE cells were also found, by phosphotyrosine Western blot analysis, to express an inordinately large number of tyrosine phosphoproteins. Direct measurement of phosphotyrosine phosphatase (PTPase) activity in SUM-52PE cell membrane protein revealed 2-3-fold lower levels of PTPase activity compared to other normal and neoplastic breast epithelial cell lines. Thus, SUM-52PE cells exhibit altered growth phenotypes not identified previously in human breast cancer cells. The constitutive activation of erbB-2 and erbB-3 in these cells, coupled with their low, membrane-associated, PTPase activity are likely to play direct roles in driving proliferation of these breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Development and characterization of new immortalized human breast cell lines

Authors: 
Journal:  Cytotechnology       Date:  1998       Impact factor: 2.058

2.  Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.

Authors:  Michelle M Martínez-Montemayor; Raysa Rosario Acevedo; Elisa Otero-Franqui; Luis A Cubano; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2011-09-02       Impact factor: 2.900

3.  USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers.

Authors:  Shiva Akhavantabasi; Hesna B Akman; Aysegul Sapmaz; Jennifer Keller; Elizabeth M Petty; Ayse E Erson
Journal:  Mamm Genome       Date:  2010-06-13       Impact factor: 2.957

4.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

Authors:  K L van Golen; Z F Wu; X T Qiao; L Bao; S D Merajver
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

5.  The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease.

Authors:  Ivette J Suárez-Arroyo; Yismeilin R Feliz-Mosquea; Juliana Pérez-Laspiur; Rezina Arju; Shah Giashuddin; Gerónimo Maldonado-Martínez; Luis A Cubano; Robert J Schneider; Michelle M Martínez-Montemayor
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 6.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Authors:  Kathryn J Chavez; Sireesha V Garimella; Stanley Lipkowitz
Journal:  Breast Dis       Date:  2010

7.  Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells.

Authors:  A E Erson; B L Niell; S K DeMers; J M Rouillard; S M Hanash; E M Petty
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

Review 8.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.

Authors:  Kenneth L van Golen; Li Wei Bao; Quintin Pan; Fred R Miller; Zhi Fen Wu; Sofia D Merajver
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models.

Authors:  Ivette J Suarez-Arroyo; Raysa Rosario-Acevedo; Alexandra Aguilar-Perez; Pedro L Clemente; Luis A Cubano; Juan Serrano; Robert J Schneider; Michelle M Martínez-Montemayor
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.